Clinical Trials - For Physicians/Providers


Phase 3 study investigating the efficacy and safety of roxadustat for treatment of anemia in patients with lower risk Myelodysplastic Syndrome (MDS) and low Red Blood Cell (RBC) transfusion burden.

Who's Eligible?

  • Diagnosed with MDS via bone marrow aspirate and biopsy
  • Low or intermediate risk MDS
  • Less than 5% bone marrow blasts
  • Hemoglobin less than or equal to 10g/dL
  • Age of 18+

Non-Small Cell Lung Cancer

The KEYNOTE B36 study is a Phase 2 pilot, single-arm, open-label study designed to evaluate the safety and effectiveness of Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T. Study patients use the device concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer (NSCLC).

Who's Eligible?

  • Diagnosed with stage III or metastatic intrathoracic NSCLC
  • Had a PD-L1 positive (TPS≥1%) tumor
  • Has not received prior treatments for NSCLC (palliative treatment is allowed)
  • Age of 22+

Non-small Cell Lung Cancer

Phase 3 study comparing niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy for patients that have remained stable or responded to first line platinum based chemo plus pembrolizumab for stage IIIB or IV non-small cell lung cancer (NSCLC).

Who's Eligible?

  • Has a histologically or cytologically confirmed diagnosis of NSCLC without known targetable driver alteration (either non-squamous or squamous histology; mixed histology is allowed)
  • Has completed at least 4 but no more than 6 cycles of platinum-based first-line induction chemotherapy with pembrolizumab
  • Age of 18+

Cutaneous Squamous Cell Carcinoma

A survivorship edpidemiology study describing the long-term real-world use and effectiveness of cemiplimab for cutaneous squamous cell carcinoma (CSCC).

Who's Eligible?

  • Currently receiving or initiating treatment with cemiplimab for CSCC
  • Continuing treatment with cemiplimab after completing previous clinical trial of cemiplimab
  • Prefer enrollment prior to third dose of cemiplimab
  • Age of 18+